NIH, pharma losers in latest 'Cures' maneuvering
This article was originally published in Scrip
Executive Summary
Two changes made to legislation aimed at overhauling the US biomedical enterprise would trim the $10bn in added funding over five years lawmakers had promised to the National Institutes of Health (NIH) – cutting it by $1.25bn – and force some biopharmaceutical makers to pay higher Medicaid rebates.